{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:09:27Z","timestamp":1790273367265,"version":"4.1.0"},"reference-count":195,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["228187"],"award-info":[{"award-number":["228187"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Economic evaluation offers policy makers a valuable tool for optimizing the use scarce healthcare resources. This scoping review aims to describe the existing scientific literature on economic evaluation and budget impact analysis of vaccine interventions, and the use of economic evidence in Africa. It highlights the current landscape and the challenges in using economic data to support vaccine policy on the continent. This study adapted and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We included peer-reviewed studies published in English between January 2000 and July 2025 that reported on cost and economic evaluations of vaccines administered to children and youth, or on the use of economic evidence for policy decision-making in Africa. A literature search was conducted across five electronic databases: Medline, Embase, Web of Science, and Scopus. The search yielded 4037 articles in total after deduction of duplication. A total of 140 articles were included in the study following title, abstract screening and full text review. The review identified a sparse but growing literature of economic evaluations related to vaccine interventions in Africa. Only a handful of countries are represented in the articles published, implying a very low production of (and likely a low demand for) economic evaluation evidence. Authorship of the articles is led mostly by researchers from institutions based outside Africa, mostly in North America and Europe. Funding of studies is mostly by Gates Foundation, Gavi, PATH, Wellcome Trust and World Health Organisation. Production and use of economic evaluation for vaccine policy in Africa have been hampered by capacity limitations in both research and policy institutions on the continent. The use of the evidence in decision making is limited. In the sphere of vaccine policy, economic evaluation is still a fledging enterprise requiring more investment.<\/jats:p>","DOI":"10.1371\/journal.pgph.0007080","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:30:43Z","timestamp":1790271043000},"page":"e0007080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Supply, demand and use of economic evidence in vaccine policymaking in Africa: A scoping review"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0323-2327","authenticated-orcid":true,"given":"Esther","family":"Mazuba","sequence":"first","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Economics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-1503","authenticated-orcid":true,"given":"Joseph","family":"Kazibwe","sequence":"additional","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Economics"]},{"name":"Lund University","place":["Malm\u00f6, Sweden"],"department":["Department of Clinical Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3032-7161","authenticated-orcid":true,"given":"Joseph","family":"Chirwa","sequence":"additional","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Economics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alick","family":"Banda","sequence":"additional","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Mathematics and Statistics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-2717","authenticated-orcid":true,"given":"Oliver","family":"Kaonga","sequence":"additional","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Economics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-5023","authenticated-orcid":true,"given":"Bona","family":"Chitah","sequence":"additional","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Economics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Orangi","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme","place":["Nairobi, Kenya"],"department":["Health Economics Research Unit"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwine","family":"Barasa","sequence":"additional","affiliation":[{"name":"KEMRI-Wellcome Trust Research Programme","place":["Nairobi, Kenya"],"department":["Health Economics Research Unit"]},{"name":"University of Oxford","place":["Oxford, United Kingdom"],"department":["Center for Tropical Medicine and Global Health, Nuffield Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-4120","authenticated-orcid":true,"given":"Felix","family":"Masiye","sequence":"additional","affiliation":[{"name":"University of Zambia","place":["Lusaka, Zambia"],"department":["Department of Economics"]},{"name":"University of Washington","place":["Seattle, Washington, United States of America"],"department":["Department of Health Metrics Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"pgph.0007080.ref001","unstructured":"World Health Organisation. Immunization Agenda 2030, Mid Term Review. 2025."},{"key":"pgph.0007080.ref002","unstructured":"UNICEF. Vaccination and Immunization Statistics. 2026. Accessed July 18, 2026. https:\/\/data.unicef.org\/topic\/child-health\/immunization\/"},{"key":"pgph.0007080.ref003","unstructured":"Immunization Agenda 2020 (IA2030). Immunization Agenda 2030. 2025. Accessed July 18, 2026. https:\/\/www.immunizationagenda2030.org\/"},{"key":"pgph.0007080.ref004","article-title":"Modeling the Impact of Vaccination for the Immunization Agenda 2030: Deaths Averted Due to Vaccination Against 14 Pathogens in 194 Countries from 2021-2030","author":"A Carter","year":"2021","journal-title":"SSRN Electronic Journal. Published online."},{"key":"pgph.0007080.ref005","unstructured":"GAVI. Gavi, The Vaccine Alliance 2025 Annual Financial Report. 2025."},{"key":"pgph.0007080.ref006","unstructured":"GAVI. Gavi Annual Progress Report 2021. 2022. Accessed May 9, 2025. https:\/\/www.gavi.org\/progress-report-2021"},{"key":"pgph.0007080.ref007","unstructured":"World Health Organisation Regional Office for Africa. Immunization. Accessed May 9, 2025. https:\/\/www.afro.who.int\/health-topics\/immunization"},{"key":"pgph.0007080.ref008","unstructured":"World Health Organisation. Business Case for WHO Immunization Activities on the African Continent 2018-2030. 2018."},{"key":"pgph.0007080.ref009","article-title":"Vaccination and vaccine-preventable diseases in Africa","volume":"24","author":"JP Sinumvayo","year":"2024","journal-title":"Sci Afr"},{"issue":"9","key":"pgph.0007080.ref010","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/vaccines11091507","article-title":"Systematic mapping of research on vaccine-preventable diseases in children in Sub-Saharan Africa: A decennial scientometric analysis","volume":"11","author":"CD Iwu","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"pgph.0007080.ref011","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jval.2019.04.002","article-title":"A Scoping review of investment cases for vaccines and immunization programs","volume":"22","author":"SY Sim","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"pgph.0007080.ref012","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/heapol\/czac092","article-title":"Factors influencing the prioritization of vaccines by policymakers in low- and middle-income countries: A scoping review","volume":"38","author":"D Guillaume","year":"2023","journal-title":"Health Policy Plan"},{"issue":"11","key":"pgph.0007080.ref013","article-title":"SMART Vaccines 2.0 decision-support platform: a tool to facilitate and promote priority setting for sustainable vaccination in resource-limited settings","volume":"5","author":"BJJ McCormick","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"8","key":"pgph.0007080.ref014","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jval.2016.04.015","article-title":"The international decision support initiative reference case for economic evaluation: An aid to thought","volume":"19","author":"T Wilkinson","year":"2016","journal-title":"Value Health"},{"key":"pgph.0007080.ref015","volume-title":"Methods for Economic Evaluation of Health Care Programmes. Fourth","author":"MF Drummond","year":"2015"},{"issue":"12","key":"pgph.0007080.ref016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-103992","article-title":"Enhancing the use of economic evidence in vaccination policy and decision making in low- and middle-income countries: A scoping review of existing strategies","volume":"15","author":"CC Okeke","year":"2025","journal-title":"BMJ Open"},{"issue":"4","key":"pgph.0007080.ref017","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/heapol\/czz027","article-title":"Value and effectiveness of National Immunization Technical Advisory Groups in low- and middle-income countries: A qualitative study of global and national perspectives","volume":"34","author":"S Bell","year":"2019","journal-title":"Health Policy Plan"},{"issue":"1","key":"pgph.0007080.ref018","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12962-021-00293-5","article-title":"Health technology assessment in sub-Saharan Africa: A descriptive analysis and narrative synthesis","volume":"19","author":"S Hollingworth","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"issue":"2","key":"pgph.0007080.ref019","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1377\/hlthaff.2015.1086","article-title":"Return on investment from childhood immunization in low- and middle-income countries, 2011-20","volume":"35","author":"S Ozawa","year":"2016","journal-title":"Health Aff"},{"issue":"1","key":"pgph.0007080.ref020","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1186\/s12913-019-4468-4","article-title":"Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries","volume":"19","author":"C Munk","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"pgph.0007080.ref021","doi-asserted-by":"crossref","first-page":"127853","DOI":"10.1016\/j.vaccine.2025.127853","article-title":"Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review","volume":"67","author":"C Anosike","year":"2025","journal-title":"Vaccine"},{"key":"pgph.0007080.ref022","unstructured":"World Health Organisation. Economics of Immunization: A Guide to the Literature and Other Resources."},{"issue":"7","key":"pgph.0007080.ref023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"pgph.0007080.ref024","first-page":"167","article-title":"What is your research question? An introduction to the PICOT format for clinicians","volume":"56","author":"JJ Riva","year":"2012","journal-title":"J Can Chiropr Assoc"},{"key":"pgph.0007080.ref025","unstructured":"Veritas Health Innovation. Covidence systematic review software. Accessed December 31, 2021. https:\/\/www.covidence.org\/"},{"issue":"15","key":"pgph.0007080.ref026","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.vaccine.2012.01.076","article-title":"Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana","volume":"30","author":"C Abbott","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref027","doi-asserted-by":"crossref","first-page":"26236","DOI":"10.3402\/ljm.v9.26236","article-title":"Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model","volume":"9","author":"S Alkoshi","year":"2014","journal-title":"Libyan J Med"},{"key":"pgph.0007080.ref028","doi-asserted-by":"crossref","first-page":"100024","DOI":"10.1016\/j.jvacx.2019.100024","article-title":"Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries","volume":"2","author":"JD Anderson","year":"2019","journal-title":"Vaccine X"},{"key":"pgph.0007080.ref029","doi-asserted-by":"crossref","unstructured":"Anderson JD, Muhib F, Rheingans R, Wierzba T. Heterogeneity in potential impact and cost-effectiveness of ETEC and Shigella vaccination in four sub-Saharan African countries. Vaccine X. 2019;3. doi: 10.1016\/J.JVACX.2019.100043","DOI":"10.1016\/j.jvacx.2019.100043"},{"issue":"5","key":"pgph.0007080.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232941","article-title":"Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria","volume":"15","author":"JD Anderson","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"pgph.0007080.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00192-4","article-title":"Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: A modelling study","volume":"11","author":"JD Anderson","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"27","key":"pgph.0007080.ref032","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2017.05.001","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings","volume":"35","author":"M Antill\u00f3n","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"pgph.0007080.ref033","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0272989X19859899","article-title":"Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study","volume":"39","author":"SMN Arifin","year":"2019","journal-title":"Med Decis Making"},{"issue":"6","key":"pgph.0007080.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067324","article-title":"Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children","volume":"8","author":"P Ayieko","year":"2013","journal-title":"PLoS One"},{"key":"pgph.0007080.ref035","article-title":"Cost-effectiveness of monovalent rotavirus vaccination of infants in Malawi: A postintroduction analysis using individual patient-level costing data","author":"N Bar-Zeev","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"25","key":"pgph.0007080.ref036","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1016\/j.vaccine.2020.04.031","article-title":"Case reduction and cost-effectiveness of the RTS,S\/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi","volume":"38","author":"GJ Bell","year":"2020","journal-title":"Vaccine"},{"key":"pgph.0007080.ref037","article-title":"The cost-effectiveness of rotavirus vaccination in Malawi","author":"SA Berry","year":"2010","journal-title":"J Infect Dis"},{"key":"pgph.0007080.ref038","article-title":"The cost-effectiveness of supplementary immunization activities for measles: A stochastic model for Uganda","author":"D Bishai","year":"2011","journal-title":"J Infect Dis"},{"key":"pgph.0007080.ref039","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1016\/j.vaccine.2018.04.061","article-title":"Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country","volume":"36","author":"EA Burger","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref040","doi-asserted-by":"crossref","first-page":"1329968","DOI":"10.1080\/16549716.2017.1329968","article-title":"Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau","volume":"10","author":"S Byberg","year":"2017","journal-title":"Glob Health Action"},{"issue":"11","key":"pgph.0007080.ref041","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/ijc.26269","article-title":"Health and economic impact of HPV 16\/18 vaccination and cervical cancer screening in Eastern Africa","volume":"130","author":"NG Campos","year":"2012","journal-title":"Int J Cancer"},{"issue":"17","key":"pgph.0007080.ref042","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.vaccine.2015.02.027","article-title":"Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: The case of Kasese district in Uganda","volume":"33","author":"C Carias","year":"2015","journal-title":"Vaccine"},{"key":"pgph.0007080.ref043","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1478-7547-12-20","article-title":"Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa","volume":"12","author":"L Channing","year":"2014","journal-title":"Cost Eff Resour Alloc"},{"issue":"10","key":"pgph.0007080.ref044","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061673","article-title":"Impact and cost-effectiveness of rotavirus vaccination in Niger: A modelling study evaluating alternative rotavirus vaccines","volume":"12","author":"F Debellut","year":"2022","journal-title":"BMJ Open"},{"key":"pgph.0007080.ref045","article-title":"Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis","author":"A Diop","year":"2015","journal-title":"Vaccine"},{"issue":"45","key":"pgph.0007080.ref046","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1016\/j.vaccine.2017.09.038","article-title":"Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of the Congo","volume":"35","author":"RH Doshi","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"pgph.0007080.ref047","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1473-3099(20)30860-4","article-title":"Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: A mathematical modelling analysis","volume":"21","author":"M Drolet","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pgph.0007080.ref048","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1186\/s12913-017-2758-2","article-title":"Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: A decision analysis using pragmatic parameter estimates for cost and programme coverage","volume":"17","author":"OI Ekwunife","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pgph.0007080.ref049","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vaccine.2016.11.042","article-title":"Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S\/AS01 in endemic Africa","volume":"35","author":"K Galactionova","year":"2017","journal-title":"Vaccine"},{"key":"pgph.0007080.ref050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13031-015-0032-y","article-title":"Comparison of impact and cost-effectiveness of rotavirus supplementary and routine immunization in a complex humanitarian emergency, Somali case study","volume":"9","author":"LM Gargano","year":"2015","journal-title":"Confl Health"},{"issue":"3","key":"pgph.0007080.ref051","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.vaccine.2016.11.070","article-title":"Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan","volume":"35","author":"LM Gargano","year":"2017","journal-title":"Vaccine"},{"issue":"32","key":"pgph.0007080.ref052","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.vaccine.2008.04.053","article-title":"Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries","volume":"26","author":"SJ Goldie","year":"2008","journal-title":"Vaccine"},{"issue":"33","key":"pgph.0007080.ref053","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1016\/j.vaccine.2021.06.059","article-title":"Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (N\u00e9oVac Study)","volume":"39","author":"A Gosset","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref054","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/heapol\/czi006","article-title":"The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique","volume":"20","author":"UK Griffiths","year":"2005","journal-title":"Health Policy Plan"},{"key":"pgph.0007080.ref055","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1016\/j.vaccine.2006.05.032","article-title":"The cost-effectiveness of alternative polio immunization policies in South Africa","volume":"24","author":"UK Griffiths","year":"2006","journal-title":"Vaccine"},{"issue":"36","key":"pgph.0007080.ref056","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.vaccine.2022.07.044","article-title":"Cost-effectiveness of rotavirus vaccination in Mozambique","volume":"40","author":"E Louren\u00e7o Guimar\u00e3es","year":"2022","journal-title":"Vaccine"},{"issue":"6","key":"pgph.0007080.ref057","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/vaccines11061058","article-title":"Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling Study","volume":"11","author":"EL Guimar\u00e3es","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"pgph.0007080.ref058","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/OLQ.0000000000000574","article-title":"Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique","volume":"44","author":"LA Haidari","year":"2017","journal-title":"Sex Transm Dis"},{"key":"pgph.0007080.ref059","doi-asserted-by":"crossref","first-page":"1383668","DOI":"10.3389\/fpubh.2024.1383668","article-title":"Sustainability of pneumococcal conjugate vaccination in Ghana: A cost-effectiveness analysis in the context of donor transition","volume":"12","author":"A-M Ibrahim","year":"2024","journal-title":"Front Public Health"},{"issue":"28","key":"pgph.0007080.ref060","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1016\/j.vaccine.2022.05.042","article-title":"Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis","volume":"40","author":"MM Janko","year":"2022","journal-title":"Vaccine"},{"issue":"7","key":"pgph.0007080.ref061","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study","volume":"2","author":"M Jit","year":"2014","journal-title":"Lancet Glob Health"},{"key":"pgph.0007080.ref062","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12962-015-0039-7","article-title":"Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin","volume":"13","author":"L Kaucley","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"pgph.0007080.ref063","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/s12889-019-7423-8","article-title":"Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: Results from a quasi-experimental evaluation","volume":"19","author":"TT Kebede","year":"2019","journal-title":"BMC Public Health"},{"issue":"12","key":"pgph.0007080.ref064","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085462","article-title":"Cost-effectiveness of human papillomavirus (HPV) vaccination in Tunisia: A modelling study","volume":"14","author":"H Khiari","year":"2024","journal-title":"BMJ Open"},{"issue":"9","key":"pgph.0007080.ref065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106836","article-title":"Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries","volume":"9","author":"S Kiatpongsan","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"pgph.0007080.ref066","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1186\/s12913-023-10283-3","article-title":"Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: A modelling study","volume":"23","author":"JA Kiendr\u00e9b\u00e9ogo","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"pgph.0007080.ref067","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2471\/BLT.06.038893","article-title":"Economic evaluation of hepatitis B vaccination in low-income countries: Using cost-effectiveness affordability curves","volume":"85","author":"S-Y Kim","year":"2007","journal-title":"Bull World Health Organ"},{"key":"pgph.0007080.ref068","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1471-2334-10-260","article-title":"Economic evaluation of pneumococcal conjugate vaccination in The Gambia","volume":"10","author":"S-Y Kim","year":"2010","journal-title":"BMC Infect Dis"},{"key":"pgph.0007080.ref069","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2334-11-174","article-title":"Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden","volume":"11","author":"S-Y Kim","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pgph.0007080.ref070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188595","article-title":"Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt","volume":"12","author":"A Kuznik","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"pgph.0007080.ref071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001432","article-title":"Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis","volume":"3","author":"RS Laufer","year":"2023","journal-title":"PLOS Glob Public Health"},{"issue":"17","key":"pgph.0007080.ref072","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.vaccine.2019.03.007","article-title":"Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya","volume":"37","author":"BY Lee","year":"2019","journal-title":"Vaccine"},{"key":"pgph.0007080.ref073","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1016\/j.vaccine.2007.06.065","article-title":"An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh","volume":"25","author":"A Levin","year":"2007","journal-title":"Vaccine"},{"key":"pgph.0007080.ref074","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12879-015-1295-z","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence","volume":"15","author":"X Li","year":"2015","journal-title":"BMC Infect Dis"},{"key":"pgph.0007080.ref075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12962-020-00219-7","article-title":"Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation","volume":"18","author":"ST Memirie","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"pgph.0007080.ref076","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40261-022-01138-6","article-title":"Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa","volume":"42","author":"DT Michaeli","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"1","key":"pgph.0007080.ref077","doi-asserted-by":"crossref","first-page":"2353480","DOI":"10.1080\/21645515.2024.2353480","article-title":"Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco","volume":"20","author":"A Mohy","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"pgph.0007080.ref078","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002528","article-title":"The case for adolescent HIV vaccination in South Africa: A cost-effectiveness analysis","volume":"95","author":"N Moodley","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"29","key":"pgph.0007080.ref079","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.vaccine.2023.05.019","article-title":"Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study","volume":"41","author":"V Mwenda","year":"2023","journal-title":"Vaccine"},{"key":"pgph.0007080.ref080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.12688\/wellcomeopenres.16224.2","article-title":"Cost-effectiveness and public health impact of RTS,S\/AS01 E malaria vaccine in Malawi, using a Markov static model","volume":"5","author":"L Ndeketa","year":"2021","journal-title":"Wellcome Open Res"},{"issue":"8","key":"pgph.0007080.ref081","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.vaccine.2021.01.031","article-title":"Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi","volume":"39","author":"F Niyibitegeka","year":"2021","journal-title":"Vaccine"},{"issue":"47","key":"pgph.0007080.ref082","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1016\/j.vaccine.2017.11.080","article-title":"Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031","volume":"36","author":"J Nonvignon","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"pgph.0007080.ref083","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30562-X","article-title":"Sustaining pneumococcal vaccination after transitioning from Gavi support: A modelling and cost-effectiveness study in Kenya","volume":"7","author":"J Ojal","year":"2019","journal-title":"Lancet Glob Health"},{"key":"pgph.0007080.ref084","doi-asserted-by":"crossref","DOI":"10.1086\/605057","article-title":"Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt","author":"O Ortega","year":"2009","journal-title":"J Infect Dis"},{"issue":"2","key":"pgph.0007080.ref085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/vaccines12020116","article-title":"Modelling the Cost-Effectiveness of Hepatitis A in South Africa","volume":"12","author":"J Patterson","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"49","key":"pgph.0007080.ref086","doi-asserted-by":"crossref","first-page":"7472","DOI":"10.1016\/j.vaccine.2018.10.068","article-title":"Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines","volume":"36","author":"C Pecenka","year":"2018","journal-title":"Vaccine"},{"issue":"12","key":"pgph.0007080.ref087","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-007211","article-title":"Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications","volume":"6","author":"C Pecenka","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"10016","key":"pgph.0007080.ref088","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: A systematic comparison of predictions from four mathematical models","volume":"387","author":"MA Penny","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"pgph.0007080.ref089","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12879-023-08105-2","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: A modeling study","volume":"23","author":"MT Phillips","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pgph.0007080.ref090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40121-018-0226-x","article-title":"Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria","volume":"8","author":"SJ Pugh","year":"2019","journal-title":"Infect Dis Ther"},{"key":"pgph.0007080.ref091","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13031-019-0188-y","article-title":"Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: A series of case studies","volume":"13","author":"JM Reardon","year":"2019","journal-title":"Confl Health"},{"key":"pgph.0007080.ref092","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12962-015-0033-0","article-title":"Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania","volume":"13","author":"GM Ruhago","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"2","key":"pgph.0007080.ref093","doi-asserted-by":"crossref","first-page":"2381468319873324","DOI":"10.1177\/2381468319873324","article-title":"Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries","volume":"4","author":"C Sauboin","year":"2019","journal-title":"MDM Policy Pract"},{"issue":"5","key":"pgph.0007080.ref094","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","article-title":"The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: A mathematical modelling study","volume":"24","author":"N Schmit","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pgph.0007080.ref095","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30219-5","article-title":"Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: A modelling study","volume":"6","author":"N Scott","year":"2018","journal-title":"Lancet Glob Health"},{"key":"pgph.0007080.ref096","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1475-2875-13-66","article-title":"Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets","volume":"13","author":"MK Seo","year":"2014","journal-title":"Malar J"},{"issue":"6","key":"pgph.0007080.ref097","doi-asserted-by":"crossref","first-page":"2114252","DOI":"10.1080\/21645515.2022.2114252","article-title":"Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt","volume":"18","author":"JP Sevilla","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"pgph.0007080.ref098","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.12.044","article-title":"Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013","volume":"33","author":"M Sibak","year":"2015","journal-title":"Vaccine"},{"key":"pgph.0007080.ref099","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.12.079","article-title":"Cost-effectiveness of rotavirus vaccination in Kenya and Uganda","volume":"33","author":"C Sigei","year":"2015","journal-title":"Vaccine"},{"issue":"44","key":"pgph.0007080.ref100","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1016\/j.vaccine.2009.08.004","article-title":"The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa","volume":"27","author":"E Sinanovic","year":"2009","journal-title":"Vaccine"},{"issue":"9559","key":"pgph.0007080.ref101","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)60195-0","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: An international economic analysis","volume":"369","author":"A Sinha","year":"2007","journal-title":"Lancet"},{"key":"pgph.0007080.ref102","article-title":"Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya","author":"JE Tate","year":"2009","journal-title":"J Infect Dis"},{"issue":"17","key":"pgph.0007080.ref103","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2010.12.122","article-title":"Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda","volume":"29","author":"JE Tate","year":"2011","journal-title":"Vaccine"},{"issue":"20","key":"pgph.0007080.ref104","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/j.vaccine.2023.04.011","article-title":"Modelling the relative cost-effectiveness of the RTS,S\/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis","volume":"41","author":"HM Topazian","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"pgph.0007080.ref105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1759-8893.2011.00057.x","article-title":"The cost effectiveness of pneumococcal conjugate vaccine in the routine infant immunisation programme of The Gambia","volume":"2","author":"MML Touray","year":"2011","journal-title":"Journal of Pharmaceutical Health Services Research"},{"issue":"26","key":"pgph.0007080.ref106","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1016\/j.vaccine.2014.03.067","article-title":"Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: A modeling-based approach","volume":"32","author":"JK Tracy","year":"2014","journal-title":"Vaccine"},{"key":"pgph.0007080.ref107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2458-11-55","article-title":"Cost-effectiveness of novel vaccines for tuberculosis control: A decision analysis study","volume":"11","author":"C-L Tseng","year":"2011","journal-title":"BMC Public Health"},{"issue":"10","key":"pgph.0007080.ref108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047511","article-title":"A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: Comparison between Rotarix and RotaTeq vaccines","volume":"7","author":"AJ van Hoek","year":"2012","journal-title":"PLoS One"},{"issue":"42","key":"pgph.0007080.ref109","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1016\/j.vaccine.2013.07.014","article-title":"Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis","volume":"31","author":"S Verguet","year":"2013","journal-title":"Vaccine"},{"key":"pgph.0007080.ref110","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.07.027","article-title":"The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana","volume":"40","author":"E Vodicka","year":"2022","journal-title":"Vaccine"},{"issue":"17","key":"pgph.0007080.ref111","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2019.03.017","article-title":"Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines","volume":"37","author":"PT Wedlock","year":"2019","journal-title":"Vaccine"},{"key":"pgph.0007080.ref112","article-title":"Cost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi. medRxiv","volume":"2024","author":"C Wenger","year":"2024","journal-title":"Published online November 23"},{"issue":"4","key":"pgph.0007080.ref113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004341","article-title":"Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi","volume":"5","author":"C Wenger","year":"2025","journal-title":"PLOS Glob Public Health"},{"issue":"14","key":"pgph.0007080.ref114","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.vaccine.2022.02.080","article-title":"Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia","volume":"40","author":"A Wondimu","year":"2022","journal-title":"Vaccine"},{"issue":"41","key":"pgph.0007080.ref115","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1016\/j.vaccine.2019.08.050","article-title":"Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis","volume":"37","author":"M Zimmermann","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref116","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-10-136","article-title":"A case study using the United Republic of Tanzania: Costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool","volume":"10","author":"R Hutubessy","year":"2012","journal-title":"BMC Med"},{"issue":"8","key":"pgph.0007080.ref117","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.vaccine.2023.01.043","article-title":"Cost of introducing and delivering RTS,S\/AS01 malaria vaccine within the malaria vaccine implementation program","volume":"41","author":"R Baral","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref118","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1186\/s12889-019-7338-4","article-title":"Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique","volume":"19","author":"S Alonso","year":"2019","journal-title":"BMC Public Health"},{"issue":"1","key":"pgph.0007080.ref119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244995","article-title":"Costs of continuing RTS,S\/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries","volume":"16","author":"R Baral","year":"2021","journal-title":"PLoS One"},{"key":"pgph.0007080.ref120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.11.057","article-title":"Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal","volume":"40","author":"T Brennan","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref121","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/tmi.12793","article-title":"Household experience and costs of seeking measles vaccination in rural Guinea-Bissau","volume":"22","author":"S Byberg","year":"2017","journal-title":"Trop Med Int Health"},{"key":"pgph.0007080.ref122","article-title":"Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso","author":"A Colombini","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pgph.0007080.ref123","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.vaccine.2003.07.007","article-title":"Cost-effectiveness of three different vaccination strategies against measles in Zambian children","volume":"22","author":"GH Dayan","year":"2004","journal-title":"Vaccine"},{"issue":"12","key":"pgph.0007080.ref124","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.vaccine.2022.02.016","article-title":"Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework","volume":"40","author":"F Debellut","year":"2022","journal-title":"Vaccine"},{"key":"pgph.0007080.ref125","doi-asserted-by":"crossref","first-page":"100583","DOI":"10.1016\/j.jvacx.2024.100583","article-title":"Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi","volume":"21","author":"F Debellut","year":"2024","journal-title":"Vaccine X"},{"issue":"4","key":"pgph.0007080.ref126","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-011316","article-title":"Cost of introducing and delivering malaria vaccine (RTS,S\/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso","volume":"8","author":"H Diawara","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"48","key":"pgph.0007080.ref127","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1016\/j.vaccine.2015.10.079","article-title":"Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data","volume":"33","author":"K Galactionova","year":"2015","journal-title":"Vaccine"},{"issue":"9","key":"pgph.0007080.ref128","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2008.12.037","article-title":"Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia","volume":"27","author":"UK Griffiths","year":"2009","journal-title":"Vaccine"},{"issue":"35","key":"pgph.0007080.ref129","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.vaccine.2016.06.050","article-title":"Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian immunisation programme: Are expansions sustainable?","volume":"34","author":"UK Griffiths","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"pgph.0007080.ref130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2471\/BLT.18.211904","article-title":"Cost of a human papillomavirus vaccination project, Zimbabwe","volume":"96","author":"A Hidle","year":"2018","journal-title":"Bull World Health Organ"},{"key":"pgph.0007080.ref131","article-title":"Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts","author":"A Hidle","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"pgph.0007080.ref132","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.vaccine.2022.11.032","article-title":"Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania","volume":"41","author":"A Hsiao","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref133","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12889-021-12108-6","article-title":"The economic impact of the switch from single- to multi-dose PCV13 vial in Benin","volume":"22","author":"PG Ilboudo","year":"2022","journal-title":"BMC Public Health"},{"issue":"8","key":"pgph.0007080.ref134","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2471\/BLT.12.113837","article-title":"Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam","volume":"91","author":"CE Levin","year":"2013","journal-title":"Bull World Health Organ"},{"issue":"6","key":"pgph.0007080.ref135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101114","article-title":"Costs of introducing and delivering HPV vaccines in low and lower middle income countries: Inputs for GAVI policy on introduction grant support to countries","volume":"9","author":"A Levin","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pgph.0007080.ref136","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/tmi.12233","article-title":"Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: The case of Malawi","volume":"19","author":"LB Madsen","year":"2014","journal-title":"Trop Med Int Health"},{"issue":"1","key":"pgph.0007080.ref137","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4269\/ajtmh.23-0412","article-title":"Modeling the cost of vaccinating a measles zero-dose child in zambia using three vaccination strategies","volume":"111","author":"J Mak","year":"2024","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"pgph.0007080.ref138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003357","article-title":"Evaluating the cost and operational context for national human papillomavirus (HPV) vaccine delivery in three regions of Ethiopia","volume":"4","author":"M Mvundura","year":"2024","journal-title":"PLOS Glob Public Health"},{"issue":"49","key":"pgph.0007080.ref139","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1016\/j.vaccine.2023.11.008","article-title":"Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries","volume":"41","author":"M Mvundura","year":"2023","journal-title":"Vaccine"},{"issue":"51","key":"pgph.0007080.ref140","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1016\/j.vaccine.2015.10.022","article-title":"A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda","volume":"33","author":"F Ngabo","year":"2015","journal-title":"Vaccine"},{"key":"pgph.0007080.ref141","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1741-7015-10-137","article-title":"Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania","volume":"10","author":"W Quentin","year":"2012","journal-title":"BMC Med"},{"issue":"2","key":"pgph.0007080.ref142","doi-asserted-by":"crossref","first-page":"2381468319896280","DOI":"10.1177\/2381468319896280","article-title":"The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries","volume":"4","author":"E Sicuri","year":"2019","journal-title":"MDM Policy Pract"},{"issue":"1","key":"pgph.0007080.ref143","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12879-024-09222-2","article-title":"An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia","volume":"24","author":"MC Simuyemba","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"67","key":"pgph.0007080.ref144","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jncimonographs\/lgae037","article-title":"Evaluating potential program cost savings with a single-dose HPV vaccination schedule: A modeling study","volume":"2024","author":"R Slavkovsky","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"pgph.0007080.ref145","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1186\/s12889-019-7793-y","article-title":"Implementation strategy and cost of Mozambique\u2019s HPV vaccine demonstration project","volume":"19","author":"C Soi","year":"2019","journal-title":"BMC Public Health"},{"issue":"17","key":"pgph.0007080.ref146","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.01.045","article-title":"Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions","volume":"32","author":"E Usuf","year":"2014","journal-title":"Vaccine"},{"issue":"48","key":"pgph.0007080.ref147","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1016\/j.vaccine.2020.10.004","article-title":"Immunization costs, from evidence to policy: Findings from a nationally representative costing study and policy translation effort in Tanzania","volume":"38","author":"K Vaughan","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"pgph.0007080.ref148","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/wber\/lhp006","article-title":"A cost\u2013benefit analysis of cholera vaccination programs in Beira, Mozambique","volume":"23","author":"M Jeuland","year":"2009","journal-title":"The World Bank Economic Review"},{"issue":"1","key":"pgph.0007080.ref149","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12962-024-00586-5","article-title":"Coverage and distributional benefit-cost of rotavirus vaccine in Uganda: An analysis of routine health facility aggregated data","volume":"22","author":"RM Kananura","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"key":"pgph.0007080.ref150","article-title":"Global eradication of measles: An epidemiologic and economic evaluation","author":"A Levin","year":"2011","journal-title":"J Infect Dis"},{"issue":"11","key":"pgph.0007080.ref151","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40261-023-01312-4","article-title":"Economic evaluation of rotavirus vaccination in children aged under five years in South Africa","volume":"43","author":"A Mohy","year":"2023","journal-title":"Clin Drug Investig"},{"key":"pgph.0007080.ref152","doi-asserted-by":"crossref","unstructured":"Ndikumukiza C, Yunusa I, Nkurunziza J, et al. Adoption of RTS, S malaria vaccine for children younger than 5 years in Rwanda: A budget impact analysis. Exploratory research in clinical and social pharmacy. 2021;3. doi: 10.1016\/J.RCSOP.2021.100063","DOI":"10.1016\/j.rcsop.2021.100063"},{"issue":"8","key":"pgph.0007080.ref153","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00220-5","article-title":"Introducing rotavirus vaccine in eight sub-Saharan African countries: A cost-benefit analysis","volume":"9","author":"CE Okafor","year":"2021","journal-title":"Lancet Glob Health"},{"key":"pgph.0007080.ref154","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vhri.2018.07.001","article-title":"The State of Health Technology Assessment in the Ethiopian Health Sector: Learning from Recent Policy Initiatives","volume":"16","author":"EA Zegeye","year":"2018","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"pgph.0007080.ref155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40258-016-0280-z","article-title":"Economic Evaluation in Ethiopian Healthcare Sector Decision Making: Perception, Practice and Barriers","volume":"15","author":"EA Zegeye","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"pgph.0007080.ref156","article-title":"Towards institutionalizing HTA in Ethiopia: Using a political economy analysis to explore stakeholder perspectives and assessing capacity needs","volume":"41","author":"DA Erku","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"pgph.0007080.ref157","article-title":"The role of evidence in the decision-making process of selecting essential medicines in developing countries: The case of Tanzania","volume":"9","author":"AT Mori","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pgph.0007080.ref158","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1017\/S0266462319000588","article-title":"Introducing health technology assessment in Tanzania","volume":"36","author":"G Surgey","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"pgph.0007080.ref159","doi-asserted-by":"crossref","first-page":"112889","DOI":"10.1016\/j.socscimed.2020.112889","article-title":"The knowledge and attitude of Ghanaian decision-makers and researchers towards health technology assessment","volume":"250","author":"R Addo","year":"2020","journal-title":"Soc Sci Med"},{"issue":"6","key":"pgph.0007080.ref160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-014904","article-title":"Designing an evidence-informed package of essential health services for Universal Health Coverage: lessons learnt and challenges to implementation in Liberia","volume":"9","author":"A Alwan","year":"2024","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pgph.0007080.ref161","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1186\/s12913-023-09673-4","article-title":"Factors influencing institutionalization of health technology assessment in Kenya","volume":"23","author":"R Mbau","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pgph.0007080.ref162","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12913-023-09276-z","article-title":"A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi","volume":"23","author":"J Mfutso-Bengo","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"pgph.0007080.ref163","doi-asserted-by":"crossref","first-page":"707","DOI":"10.15171\/ijhpm.2017.37","article-title":"How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda","volume":"6","author":"L Wallace","year":"2017","journal-title":"Int J Health Policy Manag"},{"issue":"7","key":"pgph.0007080.ref164","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/heapol\/czaa027","article-title":"How do decision-makers use evidence in community health policy and financing decisions? A qualitative study and conceptual framework in four African countries","volume":"35","author":"MB Kumar","year":"2020","journal-title":"Health Policy Plan"},{"issue":"1","key":"pgph.0007080.ref165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12962-023-00471-7","article-title":"Economic evaluations of non-communicable diseases conducted in Sub-Saharan Africa: a critical review of data sources","volume":"21","author":"SA Hollingworth","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"key":"pgph.0007080.ref166","article-title":"Research funding in Africa: navigating sustainability and shifting perspectives","author":"D Caelers","year":"2023","journal-title":"Nat Africa"},{"issue":"1","key":"pgph.0007080.ref167","first-page":"1","article-title":"Status of \u201cAfrican research and its contribution to global health research: a review and an opinion.\u201d","volume":"21","author":"N Ger","year":"2024","journal-title":"Discover public health"},{"issue":"1","key":"pgph.0007080.ref168","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1186\/s12913-024-11914-z","article-title":"Health technology assessment to support health benefits package design: A systematic review of economic evaluation evidence in Zambia","volume":"24","author":"WM Simangolwa","year":"2024","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pgph.0007080.ref169","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13643-021-01745-y","article-title":"A scoping review of researchers\u2019 involvement in health policy dialogue in Africa","volume":"10","author":"D Yimgang","year":"2021","journal-title":"Syst Rev"},{"key":"pgph.0007080.ref170","unstructured":"Pan American Health Organization. ProVac Toolkit. 2026. Accessed July 25, 2026. https:\/\/www.paho.org\/en\/provac-toolkit"},{"key":"pgph.0007080.ref171","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1478-7954-1-11","article-title":"How do Zimbabweans value health states","volume":"1","author":"J Jelsma","year":"2003","journal-title":"Popul Health Metr"},{"issue":"8","key":"pgph.0007080.ref172","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/hec.4029","article-title":"Growth and capacity for cost-effectiveness analysis in Africa","volume":"29","author":"AD Panzer","year":"2020","journal-title":"Health Econ"},{"issue":"11","key":"pgph.0007080.ref173","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060422","article-title":"Resource use, availability and cost in the provision of critical care in Tanzania: A systematic review","volume":"12","author":"J Kazibwe","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"pgph.0007080.ref174","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1377\/hlthaff.2022.00343","article-title":"Financing And Funding Gap For 16 Vaccines Across 94 Low- And Middle-Income Countries, 2011-30","volume":"42","author":"S Sriudomporn","year":"2023","journal-title":"Health Aff"},{"key":"pgph.0007080.ref175","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.34172\/ijhpm.2022.7734","article-title":"Medical Dominance in Global Health Institutions as an Obstacle to Equity and Effectiveness Comment on \u201cPower Dynamics Among Health Professionals in Nigeria: A Case Study of the Global Fund Policy Process\u201d","volume":"12","author":"SL Dalglish","year":"2023","journal-title":"Int J Health Policy Manag"},{"issue":"2","key":"pgph.0007080.ref176","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11019-025-10252-z","article-title":"Multi-professional healthcare teams, medical dominance, and institutional epistemic injustice","volume":"28","author":"A Bueter","year":"2025","journal-title":"Med Health Care Philos"},{"key":"pgph.0007080.ref177","doi-asserted-by":"crossref","first-page":"126538","DOI":"10.1016\/j.vaccine.2024.126538","article-title":"How do national immunization technical advisory groups assess and use evidence: Findings from the SYSVAC survey","volume":"43","author":"A Pilic","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"pgph.0007080.ref178","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13690-022-00808-3","article-title":"Correction to: Differences between health technology assessment topics in high- and middle-income coun8tries: a scoping review","volume":"80","author":"S Ghazinoory","year":"2022","journal-title":"Arch Public Health"},{"issue":"1","key":"pgph.0007080.ref179","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462324000266","article-title":"A situational and stakeholder analysis of health technology assessment in Zimbabwe","volume":"40","author":"B Dzingirai","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"pgph.0007080.ref180","doi-asserted-by":"crossref","first-page":"2381468319894546","DOI":"10.1177\/2381468319894546","article-title":"A Systematic Review of the Incremental Costs of Implementing a New Vaccine in the Expanded Program of Immunization in Sub-Saharan Africa","volume":"4","author":"J Brew","year":"2019","journal-title":"MDM Policy Pract"},{"issue":"1","key":"pgph.0007080.ref181","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462323002635","article-title":"Health technology assessment (HTA) readiness in Uganda: stakeholder\u2019s perceptions on the potential application of HTA to support national universal health coverage efforts","volume":"39","author":"C Mayora","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"pgph.0007080.ref182","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40273-021-01100-y","article-title":"The EQ-5D-5L Valuation Study in Egypt","volume":"40","author":"S Al Shabasy","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"pgph.0007080.ref183","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.vhri.2019.08.475","article-title":"Valuing Health State: An EQ-5D-5L Value Set for Ethiopians","volume":"22","author":"AG Welie","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"pgph.0007080.ref184","doi-asserted-by":"crossref","first-page":"101045","DOI":"10.1016\/j.vhri.2024.101045","article-title":"An EQ-5D-5L Value Set for Ghana Using an Adapted EuroQol Valuation Technology Protocol","volume":"45","author":"R Addo","year":"2025","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"pgph.0007080.ref185","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s11136-025-03930-1","article-title":"Valuing health-related quality of life: An EQ-5D-5L value set for Morocco","volume":"34","author":"A Azizi","year":"2025","journal-title":"Qual Life Res"},{"issue":"5","key":"pgph.0007080.ref186","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s11136-020-02730-z","article-title":"Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L","volume":"30","author":"J Chemli","year":"2021","journal-title":"Qual Life Res"},{"key":"pgph.0007080.ref187","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.hpopen.2025.100138","article-title":"The global landscape of country-level health technology assessment processes: A survey among 104 countries","volume":"8","author":"AJ Mirelman","year":"2025","journal-title":"Health Policy Open"},{"key":"pgph.0007080.ref188","unstructured":"Gavi. Vaccine Investment Strategy 2024. 2024. Accessed July 25, 2026. https:\/\/www.gavi.org\/our-work\/strategy\/vaccine-investment-strategy-2024"},{"key":"pgph.0007080.ref189","unstructured":"United Nations Conference on Trade and Development. Aid at the Crossroads: Trends in Official Development Assistance. 2025. Accessed May 9, 2025. https:\/\/unctad.org\/publication\/aid-crossroads-trends-official-development-assistance"},{"issue":"3","key":"pgph.0007080.ref190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","article-title":"The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review","volume":"25","author":"J Kazibwe","year":"2022","journal-title":"Value Health"},{"key":"pgph.0007080.ref191","unstructured":"World Health Organisation. WHO-CHOICE. Accessed November 11, 2020. https:\/\/www.who.int\/choice\/cost-effectiveness\/en\/"},{"issue":"6","key":"pgph.0007080.ref192","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures","volume":"11","author":"A Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"6","key":"pgph.0007080.ref193","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: A novel approach and evidence from cross-country data","volume":"3","author":"J Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"7","key":"pgph.0007080.ref194","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jval.2021.11.1375","article-title":"Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists","volume":"25","author":"A Bilinski","year":"2022","journal-title":"Value Health"},{"key":"pgph.0007080.ref195","first-page":"539","article-title":"Key actors\u2019 perspectives on cost-effectiveness analysis in Uganda: A cross-sectional survey","volume":"14","author":"JS Musuuza","year":"2014","journal-title":"BMC Health Serv Res"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0007080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:31:20Z","timestamp":1790271080000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0007080"}},"subtitle":[],"editor":[{"given":"Abram L.","family":"Wagner","sequence":"first","affiliation":[{"name":"University of Michigan","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":195,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0007080","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}